Related Experiment Video
Updated: Dec 11, 2025

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Performance of a pre-procedural Mehran score to predict acute kidney injury after percutaneous coronary intervention
Anamarys Blanco1,2, Faisal Rahim1,2, Michelle Nguyen1,2
1GME department, University of Central Florida College of Medicine, Orlando, Florida, USA.
Insights
A modified Mehran score, excluding contrast volume, effectively predicts acute kidney injury (AKI) risk in patients undergoing percutaneous coronary interventions (PCI). This pre-procedural tool aids in identifying at-risk individuals for AKI.
Area of Science:
- Nephrology
- Cardiology
- Medical Informatics
Background:
- Acute kidney injury (AKI) is a significant complication following cardiac catheterization and percutaneous coronary interventions (PCI).
- The existing Mehran score aids in AKI risk prediction but includes contrast volume, limiting its pre-procedural utility.
- A need exists for a pre-procedural risk assessment tool for AKI in PCI patients.
Purpose of the Study:
- To evaluate a modified Mehran score that excludes contrast volume for predicting AKI risk.
- To assess the discriminative ability of the pre-procedural Mehran score compared to the original Mehran score.
Main Methods:
- Retrospective analysis of 1,507 patients undergoing PCI between July 2015 and December 2017.
- Comparison of the original Mehran score with a modified version excluding contrast volume.
- Receiver-operator characteristic (ROC) curve analysis to evaluate discriminative ability.
Main Results:
- 4.6% of patients (70/1507) developed AKI.
- The modified (pre-procedural) Mehran score showed a small decrease in discrimination (AUROC 0.73 vs. 0.74).
- Net Discrimination Index (NDI) and Integrated Discrimination Index (IDI) indicated comparable performance between the scores.
Conclusions:
- The modified Mehran score, using only pre-procedural data, is a valuable tool for predicting AKI risk in PCI patients.
- Despite a minor reduction in discriminative ability, the pre-procedural score maintains clinical utility.
- This modified score enhances pre-procedural risk stratification for AKI in PCI.
Aim:
Acute kidney injury (AKI) is a known complication of patients undergoing cardiac catheterization or percutaneous coronary interventions (PCI).The Mehran score was developed to identify patients at risk for AKI after cardiac catheterization or PCI, but its use of contrast volume as part of the score calculation limits its application prior to the procedure. In this study, we evaluated the utility of a modified Mehran score that utilizes only pre-procedural data by excluding contrast volume.
Methods:
This was done in a retrospective fashion using data from patients who received PCI at our institution between July 2015 and December 2017 by evaluating the discriminative ability of the scoring systems for predicting outcomes through a receiver-operator characteristic curve analysis.
Results:
One thousand five hundred and seven patients were included in the study. A total of 70 (4.6%) patients developed AKI. The removal of contrast volume from the Mehran score resulted in a small loss of discrimination with AUROC 0.73 vs 0.74, P = .01 for the pre-procedural Mehran and the original Mehran, respectively. When compared to the original score, the pre-procedural Mehran score had a four-category net discrimination index (NRI) of -0.10 and an integrated discrimination index (IDI) for of -0.12.
Conclusion:
Despite a small loss in discrimination, there was no difference in the four-category net discrimination index between the two scores. The pre-procedural modified Mehran score is a useful clinical predictor of the risk of AKI in patients undergoing PCI.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Coronary Syndrome III: Diagnostic Studies
Acute Kidney Injury III: Clinical Manifestations

